Literature DB >> 23602943

Exposure and response prevention with or without parent management training for children with obsessive-compulsive disorder complicated by disruptive behavior: a multiple-baseline across-responses design study.

Denis G Sukhodolsky1, Bernard S Gorman, Lawrence Scahill, Diane Findley, Joseph McGuire.   

Abstract

Comorbidity with disruptive behavior disorders may have important implications for exposure-based cognitive behavioral treatments of children with OCD. Child noncompliance and parent-child conflict may interfere with performance of exposure activities and completion of therapeutic homework assignments, thus diminishing response to treatment. We investigated whether response to exposure and response prevention (ERP) can be enhanced if disruptive behavior is treated first with parent management training (PMT). A multiple-baseline across-responses design was used to investigate the effects of ERP with or without PMT in six children (age range 9-14 years) with OCD and disruptive behavior. Weekly ratings of OCD were conducted for four weeks to establish baseline. After that, children were randomly assigned to receive six weekly sessions of PMT and then twelve weekly sessions of ERP (ERP-plus-PMT condition) or to receive ERP after a six week waiting period (ERP-only condition). The outcome assessments were conducted weekly using the Child Yale-Brown Obsessive Compulsive Scale (CY-BOCS) administered by an experienced clinician, who was blind to treatment assignment. Three subjects in the ERP-plus-PMT condition evidenced a 39 percent reduction in the CY-BOCS score versus a 10 percent reduction in three subjects in the ERP-only condition. The results of our single-subject study suggest the feasibility and positive effects of combining ERP with PMT for children with OCD complicated by disruptive behavior.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23602943     DOI: 10.1016/j.janxdis.2013.01.005

Source DB:  PubMed          Journal:  J Anxiety Disord        ISSN: 0887-6185


  7 in total

1.  Quality of Life in Children and Youth with Obsessive-Compulsive Disorder.

Authors:  Eric A Storch; Brent J Small; Joseph F McGuire; Tanya K Murphy; Sabine Wilhelm; Daniel A Geller
Journal:  J Child Adolesc Psychopharmacol       Date:  2017-09-14       Impact factor: 2.576

2.  Parents' Perceptions of Internalizing and Externalizing Features in Childhood OCD.

Authors:  Andrew G Guzick; Danielle L Cooke; Joseph P H McNamara; Adam M Reid; Paulo A Graziano; Adam B Lewin; Tanya K Murphy; Wayne K Goodman; Eric A Storch; Gary R Geffken
Journal:  Child Psychiatry Hum Dev       Date:  2019-08

Review 3.  Family-Based Psychological Treatment for Obsessive Compulsive Disorder in Children and Adolescents: A Meta-analysis and Systematic Review.

Authors:  Chloë A McGrath; Maree J Abbott
Journal:  Clin Child Fam Psychol Rev       Date:  2019-12

Review 4.  Behavioral Interventions for Anger, Irritability, and Aggression in Children and Adolescents.

Authors:  Denis G Sukhodolsky; Stephanie D Smith; Spencer A McCauley; Karim Ibrahim; Justyna B Piasecka
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-01-08       Impact factor: 2.576

Review 5.  Cognitive-behavioral therapy for anxiety in children with high-functioning autism: a meta-analysis.

Authors:  Denis G Sukhodolsky; Michael H Bloch; Kaitlyn E Panza; Brian Reichow
Journal:  Pediatrics       Date:  2013-10-28       Impact factor: 7.124

Review 6.  Obsessive-compulsive disorder in children and adolescents.

Authors:  Georgina Krebs; Isobel Heyman
Journal:  Arch Dis Child       Date:  2014-11-14       Impact factor: 3.791

Review 7.  Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome: Part I-Psychiatric and Behavioral Interventions.

Authors:  Margo Thienemann; Tanya Murphy; James Leckman; Richard Shaw; Kyle Williams; Cynthia Kapphahn; Jennifer Frankovich; Daniel Geller; Gail Bernstein; Kiki Chang; Josephine Elia; Susan Swedo
Journal:  J Child Adolesc Psychopharmacol       Date:  2017-07-19       Impact factor: 2.576

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.